Ultragenyx adds new CMO with internal promotion; Autolus CFO to leave for MorphoSys — but not quite yet
As Ultragenyx looks to use the accelerated approval pathway for an increasing number of rare disease drugs, the company has promoted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
